Clinical Cardiology Alert – October 1, 2011
October 1, 2011
View Issues
-
Risk of Cardiac Events After Surgery
Perioperative cardiac events are the leading cause of surgical mortality. Thus, there has been considerable interest in predicting which patients are at highest risk. -
New Oral Anticoagulant for Atrial Fibrillation
This report is from the ARISTOTLE trial, which was just reported at the recent European Society of Cardiology meeting in Paris. Apixaban is a new direct oral factor Xa inhibitor with a favorable pharmacokinetic profile. -
Subclinical Stroke in AF Ablation
In this study, Siklody and her colleagues from three large and experienced atrial fibrillation (AF) ablation centers performed cerebral magnetic resonance imaging before and after AF ablation using three different catheter technologies. -
ACE Inhibitors/ARBs for Aortic Stenosis?
In severe symptomatic aortic stenosis (AS), surgical AVR improves mortality, but there is no medical therapy proven to slow progression of the valvular stenosis. -
Progression of Diastolic Dysfunction Predicts Incident Heart Failure
Approximately half of all cases of heart failure occur in the context of normal systolic function (heart failure with preserved ejection fraction [HFPEF]) and the number of cases is projected to rise as the population ages. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Apixaban could soon join the anticoagulation market; Chinese herbs for flu; chronic medication and discontinuation after hospitalization; and FDA actions.